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Summary
Background: Endothelin (ET)-1 has been shown to play a signiﬁcant pathogenic role
in pulmonary arterial hypertension (PAH). However, the pathobiological signiﬁcance
of increased ET-1 concentration after administration of ET receptor antagonist in
patients with PAH has not yet been fully examined.
Methods: In 16 PAH patients, plasma ET-1 concentration was measured at 0, 1, 3, 6,
and 24 h after a single 62.5mg dose of bosentan, a dual ET receptor antagonist, and
the peak and 24-h change in ET-1 concentration from baseline were examined. The
severity of PAH was evaluated by hemodynamic parameters, 6-min walk distance,
New York Heart Association (NYHA) functional class, and brain natriuretic peptide
(BNP).
Results: Plasma ET-1 concentration signiﬁcantly increased from 1.93± 0.12 to
3.36± 0.18 pg/ml after bosentan administration in PAH patients (p < 0.01). The peak-
to-baseline ratio of ET-1 concentration after bosentan administration showed a
signiﬁcant positive correlation with baseline ET-1 concentration (p < 0.05). After 4-
week bosentan administration, NYHA functional class improved in 7 patients but was
not changed in 9 patients. The optimal cut-off point of % change of ET-1 concentra-
tion at 24 h for discriminating the two groups was 30%. According to this cut-off point,
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patients were divided into the higher (n = 7) and the lower (n = 9) groups. NYHA func-
tional class did not change in the lower group, but signiﬁcantly improved (p < 0.01) in
the higher group after 4-week bosentan administration. In addition, plasma BNP levels
signiﬁcantly decreased from baseline in the higher group compared with those in the
lower group after 12-week bosentan administration (−44± 11% vs. 7± 20%, p < 0.05).
Conclusions: Although the population in this study is small and heterogeneous, mea-
surement of plasma ET-1 concentration after bosentan administration might predict
the responsiveness to bosentan treatment, and be useful in the determination of
effective therapy in treatment of PAH patients.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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gible for enrollment if they: (1) had symptomatic
PAH; (2) were in functional class 2 or higher despite
conventional therapy; (3) met the following hemo-© 2009 Japanese Colleg
reserved.
ntroduction
ulmonary arterial hypertension (PAH) is a dis-
ase of high mortality and is characterized by a
rogressive increase in pulmonary vascular resis-
ance leading to right ventricular failure and death
1,2]. Endothelial dysfunction is a principal feature
f PAH, and results in decreases in vasodilata-
ive and antiproliferative factors, e.g. prostacyclin
nd nitric oxide, and increases in vasoconstrictive
nd proliferative factors, e.g. endothelin (ET)-1
3].
ET-1 is a potent vasoconstrictor and smooth mus-
le mitogen that plays key roles in the pathobiology
f PAH. ET-1 binds to two distinct receptor isoforms
n pulmonary vessels, endothelin A (ETA) and -B
ETB) receptors [4,5]. ETA receptors are expressed
n vascular smooth muscle cells while ETB recep-
ors are expressed on both endothelial and smooth
uscle cells. Stimulation of ETA or ETB receptors
n pulmonary smooth muscle cell by ET-1 induces
asoconstriction and smooth muscle cell prolifera-
ion, while stimulation of endothelial ETB receptors
nduces the release of vasodilatative and antipro-
iferative factors [6—8]. In addition, ETB receptors
ediate pulmonary clearance of circulating ET-1
9]. Although selective upregulation of ETB recep-
ors in pulmonary artery is observed in patients
ith PAH, the level of expression of ETA recep-
or is known to be unaffected in PAH [10]. These
hanges in the ratio of ETA to ETB receptor sub-
ypes in the pulmonary vascular bed may affect the
esponsiveness to treatment of PAH patients with
T-1 antagonists.
Two types of ET receptor antagonists, dual
ETA and ETB) receptor antagonists and selective
T receptor antagonists, have recently becomeA
vailable for the treatment of PAH. A recent clin-
cal study revealed the usefulness of bosentan,
n orally active dual ET receptor antagonist, for
mprovement of exercise capacity, hemodynamics,
d
(
i
tunctional class, and survival of patients with both
ildly symptomatic and advanced PAH [11—14].
We recently reported that plasma ET-1 concen-
ration increased after bosentan administration in
atients with PAH [15]. Lofﬂer et al. [16,17] also
eported that plasma ET-1 concentration increased
fter administration of dual ET receptor antago-
ist in an animal model of pulmonary hypertension,
nd suggested that this increase was caused by dis-
lacement of ET-l from ETB receptors. The extent
f transient increase in plasma ET-1 after bosentan
dministration might thus vary depending on the
evel of expression of ETB receptors in pulmonary
essels. In addition, this increase might be a use-
ul index for the treatment of PAH patients either
sing dual or selective ET receptor antagonists. In
his study, we examined whether increase in plasma
T-1 concentration after bosentan administration is
seful for predicting the effectiveness of bosentan
reatment in PAH patients.
ubjects and methods
articipants
ixteen consecutive PAH patients, 5 men and
1 women, aged from 22 to 66 years (mean
5.8± 4.6 years), who were admitted to our insti-
ution between August 2006 and August 2008, were
ncluded in this study. Three of them had pri-
ary PAH and 13 had secondary PAH (10 connective
issue disease associated PAH and 3 congenital
eart disease associated PAH). Patients were eli-ynamic criteria: mean pulmonary artery pressure
PAP) >25mmHg at rest and mean pulmonary cap-
llary wedge pressure <15mmHg; (4) had not been
reated with bosentan. Exclusion criteria were past
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Table 1 Characteristics of the study population.
Case (no.) Age (years) Sex Diagnosis NYHA ET-1 (pg/ml) sPAP (mmHg) 6MWD (m) BNP (pg/ml)
1 35 M CHD III 2.49 79 ND 98.8
2 29 F CPAH III 2.19 46 ND 41.6
3 66 F IPAH III 2.69 101 190 167.8
4 22 M IPAH III 2.18 103 330 92.8
5 66 F CPAH III 2.06 47 296 42
6 24 F CHD II 1.15 108 505 24.9
7 65 F CPAH II 1.93 40 412 134.6
8 26 F CPAH II 1.24 21 420 19.6
9 62 F CPAH II 2.04 25 418 141.9
10 60 F CPAH IV 1.51 65 ND 253
11 59 F CPAH IV 2.75 33 ND 52
12 28 M CHD III 2.19 74 410 85.4
13 64 F CPAH IV 1.52 80 120 238
14 61 F CPAH III 1.28 32 300 45.7
15 24 M IPAH III 1.9 103 343 233.8
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a16 42 M CPAH II
IPAH, idiopathic pulmonary arterial hypertension; CHD, pulmon
CPAH, pulmonary arterial hypertension associated with connec
myocardial infarction, renal failure with a plasma
creatinine concentration >2.0mg/dl, and abnor-
mal liver function. The Ethics Committee of Osaka
University Hospital approved the study, and writ-
ten informed consent was given by each enrolled
patient.
Clinical and laboratory examination
Exercise capacity was evaluated by 6-min walk dis-
tance (6MWD) according to a standard protocol.
Systolic PAP (sPAP) was estimated from the max-
imal tricuspid regurgitation jet velocity measured
by echocardiography. Blood samples were obtained
from a peripheral vein and examined for ET-1 and
brain natriuretic peptide (BNP). Plasma was sepa-
rated and stored at −20 ◦C until analysis.
Study protocols
As for an acute study, plasma ET-1 concentration
was measured at 0, 1, 3, 6, and 24 h after a sin-
gle 62.5mg dose of bosentan. The peak-to-baseline
ratio and the 24-h-to-baseline ratio of ET-1 concen-
trations were calculated.
As for a chronic study, all patients were treated
with bosentan for 12 weeks (62.5mg bid or 31.25mg
bid) after the acute study, and clinically evaluated
at 4 and 12 weeks.Statistical analysis
Data are presented as the mean± standard error
(S.E.). Pearson’s correlation coefﬁcient was used
P
6
a
c39 450 35
rterial hypertension associated with congenital heart disease;
tissue disease; ND, not determined.
o establish the association between clinical
arameters and plasma ET-1 concentration, the
eak-to-baseline ratio, and the 24-h-to-baseline
atio. Comparison of parameters between the two
roups under different time points was made by
wo-way repeated measures analysis of variance,
ollowed by the Tukey post hoc test. Results are
onsidered to be statistically signiﬁcant at p≤ 0.05.
esults
haracteristics of study population
aseline patient characteristics are presented in
able 1. Eight patients were treated with anti-
oagulants, 6 with oxygen, 7 with diuretics, 4
ith beraprost, 2 with sildenaﬁl, and 1 with
poprostenol. For assessment of the severity of
AH, sPAP, 6MWD, plasma BNP, and ET-1 con-
entrations were determined before bosentan
dministration. Some patients could not be tested
or 6MWD because of disturbance of gait associ-
ted with connective tissue disease. Mean sPAP was
2.3± 7.4mmHg, 6MWD 350± 31m, and plasma
NP 107± 19 pg/ml in these patients.
lasma ET-1 concentrations after bosentan
dministrationlasma ET-1 concentration was measured at 0, 1, 3,
, and 24 h after a single 62.5mg dose of bosentan
dministration in 16 patients. The peak and 24-h
hange in plasma ET-1 concentration from base-
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Table 2 Plasma endothelin-1 (ET-1) concentrations after bosentan administration in PAH patients.
Case (no.) ET-1 (pg/ml) (% change)
Baseline Peak 24 h
1 2.49 3.41 (37%) 2.35 (−6%)
2 2.19 3.23 (47%) 2.10 (−3%)
3 2.69 4.30 (60%) 1.48 (−45%)
4 2.18 3.58 (64%) 2.72 (25%)
5 2.06 3.45 (67%) 2.55 (24%)
6 1.15 1.98 (72%) 1.41 (23%)
7 1.93 3.55 (84%) 1.55 (−20%)
8 1.24 3.29 (165%) 1.16 (−6%)
9 2.04 2.64 (29%) 1.72 (−16%)
10 1.51 2.72 (80%) 1.96 (30%)
11 2.75 4.31 (57%) 4.31 (57%)
12 2.19 3.78 (73%) 3.00 (37%)
13 1.52 2.88 (89%) 2.88 (89%)
14 1.28 3.04 (138%) 2.20 (72%)
15 1.9 2.81 (48%) 2.81 (48%)
16 1.74 4.86 (179%) 3.30 (90%)
.36± 0.18 (81± 11%) 2.34± 0.21 (25± 10%)
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cantly higher in the improved group than in the
unchanged group (62± 10% vs. −2± 10%, p < 0.001).
There was no signiﬁcant difference in the peak-to-
baseline ratio of ET-1 concentration between the
two groups. The optimal cut-off point of % change
at 24 h for discriminating the two groups was 30%
(Fig. 2).
According to whether % change in plasma ET-
1 concentration at 24 h was higher or lower than
30%, patients were divided into two groups, a
higher group (n = 7) and a lower group (n = 9). Base-
line patient characteristics of the higher and theMean 1.93± 0.12 3
ine are summarized in Table 2. Although plasma
T-1 concentration did not change after bosentan
dministration in normal subjects [18], it signif-
cantly increased after bosentan administration
n all PAH patients (p < 0.01). The mean time to
eak concentration was at 7.4± 2.1 h. The mean %
hange in ET-1 concentration at peak was 81± 11%,
nd at 24 h was 25± 10%.
cute study
s demonstrated above, bosentan administration
ransiently increased plasma ET-1 concentration in
ll PAH patients. We examined whether the changes
n plasma ET-1 concentration from baseline were
orrelated with clinical parameters in each PAH
atient. No correlation was found between peak
change and sPAP, 6MWD, or BNP. However, peak
change exhibited a signiﬁcant positive correla-
ion with baseline plasma ET-1 concentration in PAH
atients (Fig. 1).
hronic study
fter 4 weeks of bosentan administration, NYHA
unctional class improved in 7 (improved group),
ut was unchanged in 9 (unchanged group) of 16
atients, compared with baseline functional class.
n no patient did functional class worsen. As shown
n Fig. 2, the changes in plasma ET-1 concentration
t 24 h after single bosentan administration were
ompared in the two groups. Interestingly, the %
hange in ET-1 concentration at 24 h was signiﬁ-
Figure 1 Correlation between basal plasma ET-1 con-
centration and peak % change of ET-1 in PAH patients.
Basal ET-1 concentrations negatively correlated with
peak % change of ET-1 after a single dose of bosentan
administration (r =−0.59, p < 0.05).
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Figure 2 The % changes in ET-1 concentration at 24 h
in the unchanged group and improved group. Patients
were divided into two groups depending on whether NYHA
functional class was unchanged (n = 9) or improved (n = 7)
compared with baseline functional class after 4 weeks of
bosentan administration. The optimal cut-off point of %
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ﬁchange of ET-1 concentration at 24 h for discriminating
the two groups was 30%.
lower groups are presented in Table 3. In the lower
group, NYHA functional class did not change from
baseline after 4 weeks of bosentan administration
(NYHA 2.6± 0.2 vs. NYHA 2.4± 0.2, n.s.), while in
the higher group it signiﬁcantly improved (NYHA
3.1± 0.3 vs. NYHA 2.1± 0.3, p < 0.01). Next, plasma
BNP levels were examined at baseline and after
4 and 12 weeks of bosentan administration in 12
PAH patients (Table 4). In the lower group, the
% change in plasma BNP levels from baseline was
small at 4 and 12 weeks (−7± 17% and 7± 20%,
t
p
t
o
Table 3 Clinical characteristics of the higher group and th
Age (years) Diagnosis (IPAH/CPAH/
Higher group (n = 7) 48.3± 6.4 1/5/1
Lower group (n = 9) 43.9± 6.7 2/5/2
p value NS NS
IPAH, idiopathic pulmonary arterial hypertension; CPAH, pulmonary
ease; CHD, pulmonary arterial hypertension associated with congen
Table 4 Plasma BNP levels in the higher group and the low
BNP (pg/ml)
Baseline 4 w
Higher group (% change) 142.9 ± 44.3 76.
Lower group (% change) 94.6 ± 22.6 99.
% Change demonstrates mean of % BNP change from baseline to eac
consist of 6 patients.
* p < 0.05 vs. lower group at 12 weeks.Y. Hiramoto et al.
espectively). Whereas, in the higher group, the %
hange in plasma BNP levels signiﬁcantly decreased
ompared with those in the lower group (−44± 11%
s. 7± 20%, p < 0.05) at 12 weeks.
iscussion
n the present study, we showed that plasma ET-1
oncentration increased after bosentan administra-
ion in patients with PAH. Basal ET-1 concentration
as signiﬁcantly correlated with peak % change in
T-1 concentration after a single dose of bosen-
an. Since this increase is due to displacement of
T-1 from ETB receptors in the pulmonary vessels
16,17], elevated ET-1 concentration in the periph-
ral circulation suggests basal expression of ETB
eceptors in the pulmonary vascular bed in PAH
atients.
It was reported that plasma ET-1 concentration
as signiﬁcantly higher in PAH patients [19]. Rubens
t al. [20] showed that basal ET-1 concentration
n primary PAH patients correlated with disease
everity, and suggested that it might be a good
rognostic marker for clinical evaluation of such
atients. Therefore, peak % change might also be
seful for evaluating the severity of PAH. However,
n this study, no correlation was found between
asal ET-1 concentration and severity of disease as
valuated by hemodynamics, BNP, and 6MWD. This
nding might be explained by the study popula-
ion in this study, which included a large number of
atients with secondary PAH, or use of conventional
herapy, including sildenaﬁl, prior to admission to
ur institution.
e lower group.
CHD) ET-1 (pg/ml) sPAP (mmHg) BNP (pg/ml)
1.84± 0.19 60.9± 10.3 134.7± 38.3
2.00± 0.17 63.3± 11.6 84.9± 18.4
NS NS NS
arterial hypertension associated with connective tissue dis-
ital heart disease; NS, not signiﬁcant.
er group after bosentan treatment.
eeks 12 weeks
4 ± 25.4 (−48± 5%) 79.0 ± 34.2 (−44± 11%*)
3 ± 38.2 (−7± 17%) 98.2 ± 32.0 (7± 20%)
h period from every patient. The higher and the lower group
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We demonstrated for the ﬁrst time, that %
hange in plasma ET-1 concentration at 24 h after
single dose of bosentan is useful for predicting
he effectiveness of bosentan treatment in PAH
atients. The optimal cut-off point for prediction
hether bosentan treatment would be effective
as calculated to be 30%. Clinical outcomes of
atients with % changes in plasma ET-1 concen-
ration at 24 h higher than 30% were signiﬁcantly
etter than those of patients with the % changes
ower than 30%. Plasma BNP levels signiﬁcantly
ecreased in the higher group after 12 weeks of
osentan administration, compared with those in
he lower group. Plasma BNP levels have been
eported to be a predictor of cardiovascular events
nd death in general practice and PAH [21,22].
It has been speculated that ET-1 concentration at
4 h after single bosentan administration depends
n ET-1 clearance, and that ETB receptor plays a
ole in this [9]. Sustained high plasma levels of ET-1
ay imply relatively low expression of ETB recep-
ors in pulmonary vessels. The level of expression of
TB receptors in pulmonary vessels in PAH patients
ay thus affect responsiveness to bosentan.
The roles of ETB receptors in the pathogenesis of
AH are complex, and conﬂicting ﬁndings concern-
ng this have in fact been obtained. Upregulation of
TB receptors in pulmonary arteries was observed
n patients with PAH [10]. On the other hand, in an
nimal model of pulmonary hypertension induced
y overcirculation, expression of ETB receptors
as been reported to be increased, decreased, or
iphasic [23—25]. Black et al. [25] reported that
n 4-week-old shunt lambs, ETB receptors were
redominantly found on endothelial cells and occa-
ionally on vascular smooth muscle cells (VSMC),
hile at 8 weeks of age, a signiﬁcant subpopula-
ion of ETB receptors were localized in the VSMC
ayer. It has been reported that the expression of
TB receptors depends on the pathological stage
f PAH [26]. Because the pathological roles of
TB receptors remain complex and incompletely
nderstood, whether selective ETA or dual ETA/ETB
eceptor antagonists are more effective for the
reatment of PAH remains unclear and requires fur-
her investigation. However, the ﬁndings of the
resent study suggest the possibility that whether
elective ETA or dual ETA/ETB receptor antago-
ists are effective depends on the pathological
tage of disease in each patient, including the
evel of expression of ETB receptors in pulmonary
essels.
Signiﬁcant advances in the treatment of PAH
ave occurred in the past decade. Multiple addi-
ional agents have received approval, including
rostacyclin, phosphodiesterase type 5 inhibitors,n in pulmonary arterial hypertension 379
nd ET antagonists [27—30]. Recently, combina-
ion therapy with these agents has been employed
ore frequently [31—34], although which types of
ombinations are more effective for patients with
ifferent types of clinical features remains to be
etermined.
There are several limitations to be acknowl-
dged in the present study. First, the number of
he study subjects was relatively small and include
eterogeneous backgrounds. Second, most patients
ad connective tissue disease associated PAH and
hus, this result would not be able to generalized to
‘idiopathic’’ PAH. Further studies on clinical out-
ome after bosentan treatment for a longer period
sing large numbers of PAH patients would be nec-
ssary to conﬁrm the results.
In conclusion, measurement of plasma ET-1 con-
entration after single bosentan administration
ight predict responsiveness to chronic bosentan
reatment, and will be useful in determination of
ffective combination therapy in the treatment of
AH.
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